Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study

Published:2021-11-29 Issue:2 Volume:57 Page:252-260
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

LeBlanc Richard^ORCID,Ahmad Imran^ORCID,Terra Rafik,Boudreault Jean-Samuel,Ogez David^ORCID,Lamore Kristopher^ORCID,Delisle Jean-Sébastien,Bambace Nadia,Bernard Léa,Cohen Sandra,Kiss Thomas,Lachance Silvy^ORCID,Landais Séverine,Lemieux-Blanchard Émilie,Sauvageau Guy^ORCID,Sebag Michael,Roy Denis Claude,Roy Jean

Funder

Myeloma Canada Chair of Université de Montréal

Maryse and William Brock Chair in Applied Research into Stem Cell Transplantation (Holder J. Roy

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01532-2.pdf

Reference67 articles.

1. https://seer.cancer.gov/statfacts/html/mulmy.html.

2. Corre J, Munshi NC, Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a revision? Blood.2021;137:16–9.

3. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28:1599–605.

4. Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, et al. Epidemiological landscape of young multiple myeloma patients diagnosed earlier than 40 years: The French Experience. Blood. 2021. https://doi.org/10.1182/blood.2021011285. Online ahead of print.

5. LeBlanc R, Claveau JS, Ahmad I, Delisle JS, Bambace N, Bernard L, et al. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clin Transpl. 2020;34:e14099.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of Life in High-Risk Myeloma Patients Treated with Allogeneic Hematopoietic Cell Transplantation Followed by Bortezomib Maintenance;2024-06-18

2. Allogeneic stem cell transplantation in multiple myeloma: is there still a place?;Frontiers in Oncology;2024-06-04

3. Sequential autologous and allogeneic stem cell transplantation for treatment of primary plasma cell leukemia: A case report;Molecular and Clinical Oncology;2023-08-02

4. Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes;Current Oncology;2023-05-23

5. Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma;International Journal of Hematology;2023-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3